Oppenheimer raised the firm’s price target on TransMedics (TMDX) to $130 from $125 and keeps an Outperform rating on the shares following quarterly results. The firm cites a big Q1 beat and raise FY25 guide.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX:
- TransMedics price target raised to $125 from $105 at Piper Sandler
- TransMedics Group: Balancing Strong Q1 Performance with Growth and Margin Concerns
- TransMedics Group: Strong Performance with Cautious Outlook Amid Competitive and Reimbursement Uncertainties
- TransMedics Reports Strong Q1 2025 Financial Results
- TransMedics Group: Strong Financial Performance and Promising Growth Prospects Drive Buy Rating